Too funny ... 1st Announcement AZ will overpay for ZS pharma....2nd Announcement ZS Pharma has adverse events that will cripple drug uptake Ha Ha Ha... you rock !! On November 7, 2015, ZS Pharma (NASDAQ:ZSPH) announced interim results from their ZS005 long term safety study of its hyperkalemia treatment drug ZS-9 at during the American Society of Nephrology's [ASN] Kidney Week 2015. We will be looking in depth at two focal points of the adverse event [AE] profile: edema and hypertension. These two AEs are important to look at due to the mechanism of action [MOA] by which the study drug ZS-9 operates (detailed below). We will also be comparing ZS-9 with Relypsa's (NASDAQ:RLYP) recently FDA approved (10/21/2015) Veltassa (patiromer), a competing hyperkalemia treatment and one we will argue should be valuated equivalently.
